Greenwich Lifesciences Inc (GLSI)

May 15, 2025

Greenwich LifeSciences Delays Q1 2025 Report Filing - TipRanks

May 15, 2025

May 15, 2025

Barclays PLC Raises Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World

May 15, 2025

May 12, 2025

Long Term Trading Analysis for (GLSI) - news.stocktradersdaily.com

May 12, 2025

May 09, 2025

Greenwich LifeSciences: What The Recent Data Do For The Investment Thesis (GLSI) - Seeking Alpha

May 09, 2025

May 07, 2025

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Shares Acquired by JPMorgan Chase & Co. - Defense World

May 07, 2025

May 06, 2025

Renaissance Technologies LLC Trims Stock Position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World

May 06, 2025

May 01, 2025

(GLSI) Technical Pivots with Risk Controls - news.stocktradersdaily.com

May 01, 2025

Apr 24, 2025

HC Wainwright Issues Pessimistic Estimate for GLSI Earnings - Defense World

Apr 24, 2025

Apr 22, 2025

Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $39.00 at HC Wainwright - Defense World

Apr 22, 2025

Apr 21, 2025

Greenwich LifeSciences stock target raised to $39 at H.C. Wainwright By Investing.com - Investing.com Canada

Apr 21, 2025

Apr 21, 2025

H.C. Wainwright Boosts Greenwich LifeSciences (GLSI) Price Targe - GuruFocus

Apr 21, 2025

Apr 16, 2025

(GLSI) Proactive Strategies - news.stocktradersdaily.com

Apr 16, 2025

Apr 15, 2025

Greenwich Lifesciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 15, 2025

Apr 15, 2025

Greenwich LifeSciences, Inc. SEC 10-K Report - TradingView

Apr 15, 2025

Apr 14, 2025

Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Monday - Defense World

Apr 14, 2025

Apr 12, 2025

GREENWICH LIFESCIENCES Earnings Preview: Recent $GLSI Insider Trading, Hedge Fund Activity, and More - Nasdaq

Apr 12, 2025

Apr 11, 2025

Greenwich Lifesciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView

Apr 11, 2025

Apr 08, 2025

Greenwich Lifesciences CEO Snehal Patel acquires $32,760 in stock - Investing.com

Apr 08, 2025

Apr 08, 2025

Greenwich Lifesciences CEO Snehal Patel acquires $32,760 in stock By Investing.com - Investing.com UK

Apr 08, 2025

Apr 07, 2025

Greenwich LifeSciences CEO Snehal Patel buys $48,015 in common stock By Investing.com - Investing.com Canada

Apr 07, 2025

Apr 07, 2025

Greenwich LifeSciences CEO Snehal Patel buys $48,015 in common stock - Investing.com Australia

Apr 07, 2025

Apr 03, 2025

Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial - Curetoday

Apr 03, 2025

Apr 03, 2025

Greenwich LifeSciences reports progress on FLAMINGO-01 trial By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

GLSI stock touches 52-week low at $9.05 amid market challenges By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

GLSI stock touches 52-week low at $9.05 amid market challenges - Investing.com

Apr 03, 2025

Apr 03, 2025

Greenwich Lifesciences Provides Global Update On Flamingo-01 - marketscreener.com

Apr 03, 2025

Apr 03, 2025

Greenwich LifeSciences Provides Global Update on FLAMINGO-01 - GlobeNewswire

Apr 03, 2025

Apr 03, 2025

Greenwich LifeSciences reports progress on FLAMINGO-01 trial - Investing.com

Apr 03, 2025

Apr 03, 2025

Major Breakthrough: Cancer Prevention Trial Reports Positive Data, Elite Hospitals Join - Stock Titan

Apr 03, 2025

Apr 02, 2025

Greenwich LifeSciences (GLSI) Shares Surge on Positive Phase 3 D - GuruFocus

Apr 02, 2025

Apr 02, 2025

Flamingo cancer vaccine in phase III pink, Greenwich time nigh? - BioWorld MedTech

Apr 02, 2025

Apr 02, 2025

Pre-market Movers: IBG, JYD, SBFM, SPWH, RSLS… - RTTNews

Apr 02, 2025

Apr 02, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Apr 02, 2025

Apr 02, 2025

Greenwich LifeSciences stock rises on cancer shot data (GLSI) - Seeking Alpha

Apr 02, 2025

Apr 02, 2025

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial - The Manila Times

Apr 02, 2025

Apr 02, 2025

Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial - MarketScreener

Apr 02, 2025

Apr 02, 2025

Clinical Trial Success: GLSI's Breast Cancer Therapy Shows Promising Results in Expanded Patient Group - Stock Titan

Apr 02, 2025

Apr 02, 2025

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7%Time to Sell? - MarketBeat

Apr 02, 2025

Apr 01, 2025

Recent 15% decline may not have gone down well with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who've been purchasing recently - simplywall.st

Apr 01, 2025

Mar 31, 2025

Greenwich LifeSciences Delays Yearly Report Filing - TipRanks

Mar 31, 2025

Mar 31, 2025

How To Trade (GLSI) - news.stocktradersdaily.com

Mar 31, 2025

Mar 27, 2025

Greenwich LifeSciences Extends Lock-Up Period for Directors, Officers to March 2026 - MarketScreener

Mar 27, 2025

Mar 27, 2025

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Major Insider Confidence Signal: Greenwich LifeSciences Leadership Locks Shares Until 2026 - Stock Titan

Mar 27, 2025

Mar 26, 2025

HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx, Alteogen - Barchart

Mar 26, 2025

Mar 26, 2025

HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA - openPR.com

Mar 26, 2025

Mar 25, 2025

GLSI stock touches 52-week low at $10.52 amid market challenges - Investing.com

Mar 25, 2025

Mar 17, 2025

Greenwich LifeSciences gets DSMB approval to continue late-stage trial of GLSI-100 - MSN

Mar 17, 2025

Mar 17, 2025

Greenwich LifeSciences Says Preliminary Safety Data for Breast Cancer Therapy Appears Consistent With Prior Trials - Marketscreener.com

Mar 17, 2025